247 related articles for article (PubMed ID: 33350263)
1. [Preparation and characterization of icariin nanosuspension and lyophilized powder].
Hui-Rong XI; Hui-Ping MA; Ke-Ming C; Xiao-Shuan L
Zhongguo Zhong Yao Za Zhi; 2020 Oct; 45(20):4902-4908. PubMed ID: 33350263
[TBL] [Abstract][Full Text] [Related]
2. [Preparation and quality evaluation of orodispersible film containing ginkgolide B novel nanosuspension lyophilized powder].
Jing W; Jun-Jun Z; Bao-de S; Ting Z; Bo D; Ya-Ning Z; Hai-Long Y
Zhongguo Zhong Yao Za Zhi; 2020 Nov; 45(22):5504-5510. PubMed ID: 33350212
[TBL] [Abstract][Full Text] [Related]
3. [Preparation of herpetolide A nanosuspension lyophilized powder and evaluation of its anti-hepatitis B virus activity].
Zhong YJ; Liu QC; Zhang T; Liu X; Wang LQ; Yuan HL
Zhongguo Zhong Yao Za Zhi; 2020 Mar; 45(5):1076-1081. PubMed ID: 32237449
[TBL] [Abstract][Full Text] [Related]
4. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
Gajera BY; Shah DA; Dave RH
Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
[TBL] [Abstract][Full Text] [Related]
5. [Preparation of astilbin amorphous nanosuspension and its
Wang XH; Zhong RN; Shen BD; Shen CY; Liu X; Dai B; Yuan HL
Zhongguo Zhong Yao Za Zhi; 2018 Apr; 43(8):1626-1632. PubMed ID: 29751709
[TBL] [Abstract][Full Text] [Related]
6. Enhancing Betulinic Acid Dissolution Rate and Improving Antitumor Activity via Nanosuspension Constructed by Anti-Solvent Technique.
Li S; Zhang J; Fang Y; Yi J; Lu Z; Chen Y; Guo B
Drug Des Devel Ther; 2020; 14():243-256. PubMed ID: 32021108
[TBL] [Abstract][Full Text] [Related]
7. Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box-Behnken Design.
Kassem MAA; ElMeshad AN; Fares AR
AAPS PharmSciTech; 2017 May; 18(4):983-996. PubMed ID: 27506564
[TBL] [Abstract][Full Text] [Related]
8. Development of a chemically stable 10-hydroxycamptothecin nanosuspensions.
Pu X; Sun J; Wang Y; Wang Y; Liu X; Zhang P; Tang X; Pan W; Han J; He Z
Int J Pharm; 2009 Sep; 379(1):167-73. PubMed ID: 19505545
[TBL] [Abstract][Full Text] [Related]
9. [Preparation, characterization and dissolution characteristics of dragon's blood extract nanosuspensions].
Wang LF; Chen XN; Li J; Tu PF; Wang JL
Zhongguo Zhong Yao Za Zhi; 2019 Jun; 44(11):2236-2243. PubMed ID: 31359648
[TBL] [Abstract][Full Text] [Related]
10. Preparation and characterization of freeze-dried 2-methoxyestradiol nanoparticle powders.
Du B; Li XT; Zhao Y; A YM; Zhang ZZ
Pharmazie; 2010 Jul; 65(7):471-6. PubMed ID: 20662313
[TBL] [Abstract][Full Text] [Related]
11. Preparation and Characterization of Stable Nanosuspension for Dissolution Rate Enhancement of Furosemide: A Quality by Design (QbD) Approach.
Marzan AL; Tabassum R; Jahan B; Asif MH; Reza HM; Kazi M; Alshehri SM; de Matas M; Shariare MH
Curr Drug Deliv; 2018; 15(5):672-685. PubMed ID: 29359667
[TBL] [Abstract][Full Text] [Related]
12. Fabrication of Ibrutinib Nanosuspension by Quality by Design Approach: Intended for Enhanced Oral Bioavailability and Diminished Fast Fed Variability.
Rangaraj N; Pailla SR; Chowta P; Sampathi S
AAPS PharmSciTech; 2019 Oct; 20(8):326. PubMed ID: 31659558
[TBL] [Abstract][Full Text] [Related]
13. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability.
Nagaraj K; Narendar D; Kishan V
Drug Dev Ind Pharm; 2017 Jul; 43(7):1186-1196. PubMed ID: 28271908
[TBL] [Abstract][Full Text] [Related]
14. [Preparation and in vitro release of ginkgolide B nanosuspension].
Wang J; Zhu JJ; Shen BD; Zhang T; Zhu YN; Yuan HL
Zhongguo Zhong Yao Za Zhi; 2020 Apr; 45(7):1657-1663. PubMed ID: 32489046
[TBL] [Abstract][Full Text] [Related]
15. Fabrication of drug nanoparticles by evaporative precipitation of nanosuspension.
Kakran M; Sahoo NG; Li L; Judeh Z; Wang Y; Chong K; Loh L
Int J Pharm; 2010 Jan; 383(1-2):285-92. PubMed ID: 19781606
[TBL] [Abstract][Full Text] [Related]
16. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation.
Hong C; Dang Y; Lin G; Yao Y; Li G; Ji G; Shen H; Xie Y
Int J Pharm; 2014 Dec; 477(1-2):251-60. PubMed ID: 25445518
[TBL] [Abstract][Full Text] [Related]
17. Preparation and characterization of betulin nanoparticles for oral hypoglycemic drug by antisolvent precipitation.
Zhao X; Wang W; Zu Y; Zhang Y; Li Y; Sun W; Shan C; Ge Y
Drug Deliv; 2014 Sep; 21(6):467-79. PubMed ID: 24479653
[TBL] [Abstract][Full Text] [Related]
18. Preparation, Characterization and In Vivo Assessment of Repaglinide Nanosuspension for Oral Bioavailability Improvement.
Zawar LR; Bari SB
Recent Pat Drug Deliv Formul; 2018; 12(3):162-169. PubMed ID: 30003863
[TBL] [Abstract][Full Text] [Related]
19. Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension.
Li W; Yang Y; Tian Y; Xu X; Chen Y; Mu L; Zhang Y; Fang L
Int J Pharm; 2011 Apr; 408(1-2):157-62. PubMed ID: 21295124
[TBL] [Abstract][Full Text] [Related]
20. Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers: I. A Design of Experiment approach.
Karakucuk A; Celebi N; Teksin ZS
Eur J Pharm Sci; 2016 Dec; 95():111-121. PubMed ID: 27181836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
